Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, J | - |
dc.contributor.author | Yoo, BC | - |
dc.contributor.author | Lee, HS | - |
dc.contributor.author | Yoo, HW | - |
dc.contributor.author | Yoo, HH | - |
dc.contributor.author | Kang, MJ | - |
dc.contributor.author | Kim, DH | - |
dc.date.accessioned | 2024-01-21T03:39:10Z | - |
dc.date.available | 2024-01-21T03:39:10Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2006-02 | - |
dc.identifier.issn | 0163-4356 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/135777 | - |
dc.description.abstract | The purpose of this study was to develop an analytical method for the determination of 2'-fluoro-5-metliyl-beta-1-arabinofuranosyl uracil triphosphate (L-FMAU-TP) in human peripheral blood rnononuclear cells (PBMCs), and its application in the determination of cellular levels of L-FMAU-TP in PBMCs isolated front patients treated with 2'-fluoro-5-methyl-beta-1-arabinofurinosyl uracil (L-FMAU). An ion-pairing liquid chromatography (IPC) method, coupled with negative ion electrospray ionization tandem mass spectrometry (ESI-MS/MS), was developed for the accurate and repeatable detection of L-FMAU-TP. with a limit of detection of 1.6 pmol/10(6) cells. The calibration curve for L-FMAU-TP was linear over the concentration range 1.6 to 80 pmol/10(6) cells. The intra- and inter-day precision was lower than 11.2%, and the accuracy was between 97.1 and 106.9%. When applied to the determination of L-FMAU-TP in PBMCs isolated from HBV-infected patients undergoing L-FMAU treatment, the levels reached a steady state concentration 4 weeks after daily sin(2le oral administration of 20 Ing L-FMAU, and these levels were maintained for up to 12 weeks, but then decreased 12 weeks after drua cessation. The tenninal half-life of L-FMAU-TP in PBMCs after druLy cessation was estimated to be 15.6 days. | - |
dc.language | English | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | LAMIVUDINE TRIPHOSPHATE | - |
dc.subject | AGENT | - |
dc.subject | NUCLEOSIDE | - |
dc.subject | PHOSPHATE | - |
dc.subject | DRUGS | - |
dc.title | Rapid quantitative determination of L-FMAU-TP from human peripheral-blood mononuclear cells of hepatitis B virus-infected patients treated with L-FMAU by ion-pairing, reverse-phase, liquid chromatography/electrospray tandem mass spectrometry | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/01.ftd.0000194027.12107.11 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC DRUG MONITORING, v.28, no.1, pp.131 - 137 | - |
dc.citation.title | THERAPEUTIC DRUG MONITORING | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 131 | - |
dc.citation.endPage | 137 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000235129400026 | - |
dc.identifier.scopusid | 2-s2.0-33745480150 | - |
dc.relation.journalWebOfScienceCategory | Medical Laboratory Technology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.relation.journalResearchArea | Medical Laboratory Technology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | LAMIVUDINE TRIPHOSPHATE | - |
dc.subject.keywordPlus | AGENT | - |
dc.subject.keywordPlus | NUCLEOSIDE | - |
dc.subject.keywordPlus | PHOSPHATE | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordAuthor | L-FMAU-TP | - |
dc.subject.keywordAuthor | PBMCs | - |
dc.subject.keywordAuthor | ion-pairing liquid chromatography | - |
dc.subject.keywordAuthor | tandem mass spectrometry | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.